WINT — Windtree Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Windtree Therapeutics Estimates That As Of March 31, Cash And Cash Equivalents Were Approximately $4.2 Million
Brief: Windtree Therapeutics Quarterly Net Loss $13.01 Per Share
Brief: Windtree Regains Compliance With Nasdaq
Brief: Windtree Therapeutics Has No Cash Deposits Or Securities At Silicon Valley Bank
Brief: Windtree Therapeutics Issues New Istaroxime Patent From U.S. Patent, Trademark Office
Brief: Windtree Therapeutics Inc - On January 17, John Hamill CFO Notified Co Of His Decision To Resign Effective As Of January 27, 2023
Brief: Nasdaq Grants Windtree Therapeutics 180-Day Extension To Regain Compliance
Windtree Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Windtree Therapeutics Reports Q3 Results, Provides Key Business Updates
Windtree Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-EV stocks, Sarepta, Senti Biosciences
U.S. STOCKS ON THE MOVE-Peloton, Rivian, Proterra, Gamida
U.S. STOCKS ON THE MOVE-Axsome Therapeutics, Miners, Bed Bath & Beyond
U.S. STOCKS ON THE MOVE-Windtree Therapeutics, Axcella, Occidental
Windtree Therapeutics up as heart disease drug meets main goal in mid-stage study
Brief: Windtree Therapeutics Announces Istaroxime Late Breaker Abstract From Its Positive Phase 2 Study In Early Cardiogenic Shock (Seismic) To Be Presented At Heart Failure Society Of America
U.S. STOCKS ON THE MOVE-Macy, Tritium, Ares Management
U.S. STOCKS ON THE MOVE-Energy firms, Natgas companies, ProPetro
Windtree surges on licensing deal for lung disease therapy